"Comparison of Different Antisense Oligonucleotides Against the BCR/ABL Junction in Chronic Myelogenous Leukemia: Cellular Pharmacology and in Vitro Efficacy."

According to the authors' abstract of an article published in International Journal of Oncology, "The activity of the BCR/ABL hybrid gene is associated with a growth advantage of the chronic myelogenous leukemia (CML) stem cell. Suppression of BCR/ABL hybrid gene expression can be a valuable tool for leukemic cell purging. Antisense oligonucleotides (ODNs) have the capacity to specifically downregulate gene expression. Data reported on the effect they have on BCR/ABL hybrid gene expression are controversial. We present data illustrating that prolongation of ODN half-life by means of chemical or sequence modification has only limited specific growth suppressive effect on...

Want to see the full article?

• Purchase this article for only $3.00